OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
|
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [41] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Real-world experience with sipuleucel-T (Sip-T) in Asian men with castrate-resistant prostate cancer (CRPC).
    Zhang, Jingsong
    Liu, Ming
    Pan, Jiahua
    Wei, Xiao X.
    Harmon, Matthew
    Azzolina, John
    Flanders, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [44] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [46] Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
    Sims, Robert B.
    JOURNAL OF CANCER, 2011, 2 : 357 - 359
  • [47] PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).
    Harrison, Michael Roger
    Khouri, Michel
    Armstrong, Andrew J.
    Zhang, Tian
    McNamara, Megan Ann
    Anand, Monika
    Bratt, Ellen
    Hood, Hillary
    Coyne, Brian
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).
    Quinn, David I.
    Drake, Charles G.
    Dreicer, Robert
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Corman, John M.
    Concepcion, Raoul S.
    Pieczonka, Christopher Michael
    Chang, Nancy N.
    DeVries, Todd
    Sheikh, Nadeem A.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [50] Olaparib in metastatic castrate-resistant prostate cancer
    不详
    BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
12345